173 related articles for article (PubMed ID: 25703642)
21. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
22. Primary cutaneous small/medium CD4+ T-Cell lymphoma occurring during treatment with vemurafenib for advanced melanoma.
Garrido MC; Riveiro-Falkenbach E; Ruano Y; Ortiz P; Rodriguez-Peralto JL
Am J Dermatopathol; 2015 Jun; 37(6):440-3. PubMed ID: 25357018
[TBL] [Abstract][Full Text] [Related]
23. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
[No Abstract] [Full Text] [Related]
24. Hyperkeratosis of the nipple associated with acanthosis nigricans: treatment with topical calcipotriol.
Lee HW; Chang SE; Lee MW; Choi JH; Moon KC; Koh JK
J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):529-30. PubMed ID: 15761439
[No Abstract] [Full Text] [Related]
25. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
26. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
27. Eosinophilic Infiltrates in Vemurafenib-Associated Verrucous Keratoses.
Longhurst WD; Honda K; Koon HB; Gerstenblith MR
Am J Dermatopathol; 2016 Oct; 38(10):766-8. PubMed ID: 27533075
[No Abstract] [Full Text] [Related]
28. Cutaneous adverse events during vemurafenib therapy.
Chandrakumar SF; Yeung J
J Cutan Med Surg; 2014; 18(4):223-8. PubMed ID: 25008438
[TBL] [Abstract][Full Text] [Related]
29. Hyperkeratosis of the nipple and areola: a histopathologic pitfall.
Sander D; Dietmaier W; Wobser M; Haferkamp S
J Dtsch Dermatol Ges; 2018 Nov; 16(11):1368-1370. PubMed ID: 30295995
[No Abstract] [Full Text] [Related]
30. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
31. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
32. Vemurafenib-associated keratoses with genetic heterogeneity of RAS.
Loh E; Hosler GA
J Drugs Dermatol; 2014 Apr; 13(4):495-7. PubMed ID: 24719071
[TBL] [Abstract][Full Text] [Related]
33. Vitiligo of the Face in a Patient Treated With Vemurafenib for Metastatic Melanoma.
Nasca MR; Lacarrubba F; Ferraù F; Micali G
J Drugs Dermatol; 2016 Jun; 15(6):766-8. PubMed ID: 27272087
[TBL] [Abstract][Full Text] [Related]
34. Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma.
Boudewijns S; Gerritsen WR; Koornstra RH
BMC Cancer; 2014 Dec; 14():967. PubMed ID: 25515496
[TBL] [Abstract][Full Text] [Related]
35. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
[No Abstract] [Full Text] [Related]
36. Reaccion acneiforme noduloquistica secundaria a vemurafenib con buena respuesta a isotretinoina oralSevere acneiform eruption associated with vemurafenib with response to isotretinoin.
Elosua-Gonzalez M; Lopez-Estebaranz JL; Garcia-Zamora E; Vela-Ganuza M; Rodrigez-Vasquez X
Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677858
[TBL] [Abstract][Full Text] [Related]
37. Nevoid hyperkeratosis of the nipple and areola: a distinct entity.
Baykal C; Büyükbabani N; Kavak A; Alper M
J Am Acad Dermatol; 2002 Mar; 46(3):414-8. PubMed ID: 11862178
[TBL] [Abstract][Full Text] [Related]
38. Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Sufficool KE; Hepper DM; Linette GP; Hurst EA; Lu D; Lind AC; Cornelius LA
J Cutan Pathol; 2014 Jul; 41(7):568-75. PubMed ID: 24641301
[TBL] [Abstract][Full Text] [Related]
39. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
40. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]